| 000 | 01801 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250513091034.0 | ||
| 264 | 0 | _c19960717 | |
| 008 | 199607s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChaushu, G | |
| 245 | 0 | 0 |
_aSalivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cFeb 1996 |
||
| 300 |
_a237-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Viral _xanalysis |
| 650 | 0 | 4 | _aAntibody Specificity |
| 650 | 0 | 4 |
_aB-Lymphocytes _xtransplantation |
| 650 | 0 | 4 |
_aBone Marrow Transplantation _xadverse effects |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aCytomegalovirus _ximmunology |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xetiology |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGraft vs Host Disease _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 |
_aImmunoglobulin G _xanalysis |
| 650 | 0 | 4 |
_aImmunoglobulin M _xanalysis |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xpharmacokinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParotid Gland _xmetabolism |
| 650 | 0 | 4 |
_aPlasma Cells _xtransplantation |
| 650 | 0 | 4 |
_aSaliva _ximmunology |
| 650 | 0 | 4 |
_aSalivary Proteins and Peptides _xanalysis |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aVirus Activation |
| 700 | 1 | _aChaushu, S | |
| 700 | 1 | _aSlavin, S | |
| 700 | 1 | _aOr, R | |
| 700 | 1 | _aGarfunkel, A A | |
| 700 | 1 | _aYefenof, E | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 17 _gno. 2 _gp. 237-41 |
|
| 999 |
_c8639213 _d8639213 |
||